Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.81 |
| ▸ | LMNA | P02545 | 6/20 | 0.81 |
| ▸ | GAA | P10253 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.81 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide Phosphate SCHEMBL29711333 | 1.00 | CYP3A4 (0.81) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL29564759 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13524290 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL1649994 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL15118344 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318053 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL3621 | 0.94 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL15395274 | 0.93 | CYP3A4 (0.81) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL13529268 | 0.93 | CYP3A4 (0.81) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL8727825 | 0.93 | CYP3A4 (0.80) | CYP3A4LMNAGAASMN1; SMN2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2298768-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1761528-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | Japan Tobacco, Inc. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| WO-2005121142-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO’2,3-D! PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC. (JP) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TOP2A 3118/4885CYP3A4 1505/4885LMNA 3156/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TOP2A 3118/4885CYP3A4 1505/4885LMNA 3156/4885 |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TOP2A 394/4885CYP3A4 2219/4885LMNA 4633/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TOP2A 448/4885CYP3A4 209/4885LMNA 2176/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | TOP2A 1293/4885CYP3A4 342/4885LMNA 3505/4885 |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | CDKN1A, CDK2, CDC25A | TOP2A 620/4885CYP3A4 3727/4885LMNA 4015/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TOP2A 394/4885CYP3A4 2219/4885LMNA 4633/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TOP2A 394/4885CYP3A4 2219/4885LMNA 4633/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | TOP2A 3118/4885CYP3A4 1505/4885LMNA 3156/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | TOP2A 448/4885CYP3A4 209/4885LMNA 2176/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | TOP2A 758/4885CYP3A4 134/4885LMNA 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.